- DESCRIPTION
- TABLE OF CONTENTS
- METHODOLOGY
- DOWNLOAD PDF
Hematology Analyzers and Reagents Market by Product [Instrument (PoC,5 part 6 part), Reagents, Slide Stainers] & Service, Price (High, Mid, Low), Application (Infectious Diseases, Blood Cancer), End User (Hospital, CTL, Govt Lab) Global Forecast to 2031
USD USD 10.33 BN
MARKET SIZE, 2031
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global hematology analyzers & reagents market is expected to grow from USD 7.57 billion in 2026 to USD 10.33 billion by 2031, representing a CAGR of 6.4%. There is a noticeable move towards automation in the hematology analyzers and reagents market. High first-pass yield and auto-validation are two features that have become more desirable in this market segment, as they help reduce repeat analyses and improve productivity. Furthermore, improvements in the design of the analyzers have made it possible to decrease reagent consumption, provide more walk-away time, and reduce manual intervention.
KEY TAKEAWAYS
-
BY REGION
The Asia Pacific region is projected to witness the highest CAGR of 7.7% in the global hematology analyzers & reagents market.
-
BY PRODUCT & SERVICES
The hematology analyzers & reagents segment is estimated to account for the highest market share of 60.5% in 2025.
-
BY PRICE RANGE
The mid-range hematology analyzers segment is expected to register the highest CAGR of 6.3%.
-
BY APPLICATION
The blood cancer segment is expected to dominate the market with 34% revenue share in 2025.
-
BY USAGE TYPE
The standalone analyzers segment accounted for the largest market share of 59% in 2025.
-
BY END USER
The commercial service providers segment is projected to grow at the fastest rate of 7.3% from 2026 to 2031.
-
COMPETITIVE LANDSCAPE: KEY PLAYERS
Abbott Laboratories (US), Danaher (US), Siemens Healthineers (Germany), Sysmex Corporation (Japan), Bio-Rad Laboratories (US), and Horiba (Japan) are identified as some of the star players in the hematology analyzers & reagents market, given their strong global market presence, extensive portfolios, advanced R&D capabilities, and well-established distribution networks across developed and emerging regions.
-
COMPETITIVE LANDSCAPE: OTHER PLAYERS
These companies offer unique products that have started occupying a niche for themselves within the industry. Their business and product superiority is yet to be matched when compared to some other leading start-up firms. Some of the most successful firms in this segment include Drucker Diagnostics (US), ELITechGroup SAS (India), Accurex (India), and Analyticon Biotechnologies GmbH (Germany).
There is a noticeable move towards automation in the hematology analyzers and reagents market. High first-pass yield and auto-validation are two features that have become more desirable in this market segment, as they help reduce repeat analyses and improve productivity. Furthermore, improvements in the design of the analyzers have enabled reduced reagent consumption, increased walk-away time, and reduced manual intervention.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
Certain trends and technological developments are reshaping the landscape of hematology analyzers and reagents. There is a clear trend among industry companies towards replacing traditional cell counters with more modern, sophisticated instruments capable of 5- and 6-part differentials, digital morphology, and flow cytometry. Besides, there are new products on the market for reagents and disposables that enable faster processing and increased result accuracy. Furthermore, there is an increase in the adoption of AI technologies, automation, and middleware for analysis by hospitals and laboratories.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
OPPORTUNITIES
Impact
Level
-
Expansion of AI-enabled telehematology and remote diagnostics
-
Adoption of precision diagnostics enabling advanced cell profiling, rare cell detection, and early disease identification
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
AI is driving changes in the diagnostic hematology landscape, with a transition from traditional, manual, and parameter-limited tests to automated, information-driven, and intelligent systems that provide more in-depth morphological evaluation, greater speed, and improved accuracy. Hematology tests using artificial intelligence are leading to the complete automation of laboratory workflows, from sample preparation through to diagnosis and reporting, while limiting the need for human intervention and reducing inconsistencies across individuals. Digital morphology and advanced image analysis help detect unusual cell population distribution patterns, and AI-based systems can facilitate remote diagnosis and telehematological services. Moreover, artificial intelligence is used to address the shortage of qualified personnel by automating analysis. Morphometric and predictive analysis are opening up novel possibilities, such as biomarker detection, disease diagnosis, and prognosis assessment.
The adoption of advanced hematology analyzers is limited by high capital costs and total cost of ownership, restricting their use mainly to large hospitals and reference labs. These systems require significant investment in infrastructure, maintenance, and reagents, making them less accessible for small and mid-sized laboratories. As a result, cost-sensitive facilities, especially in emerging markets, continue to rely on lower-cost or semi-automated systems. High-end analyzers typically cost USD 50,000–120,000, while mid-range systems range from USD 30,000–80,000, making cost a key barrier to adoption.
Telehematology is being enhanced by combining AI with digital imaging and telemedicine. With the aid of artificial intelligence, cell examination can be automated, making blood testing easier. The use of AI systems will facilitate more accurate diagnoses of conditions like anemia and leukemia, as well as other medical conditions that require blood tests. Telemedicine technology can enhance tele-hematology by providing access to remote slide viewing and expert consultations.
Modern hematology instruments produce a growing volume of complex data, which poses challenges for analysis and processing. However, innovations such as microfluidics and POCT devices enable the development of small-scale equipment capable of conducting full-scale tests. Although artificial intelligence helps improve diagnostics, its application requires high-quality data.
HEMATOLOGY ANALYZERS AND REAGENTS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
It offers specialized contrast agents and syringeless injectors (like Max 3) for MRI and ultrasound (CEUS) applications. | Ensures scalable workflows, consistent results, and improved lab efficiency |
|
|
It delivers DxH series analyzers with integrated automation and AI-enabled digital morphology. | Enables precise results, faster turnaround, and reduced manual intervention |
|
|
It offers Atellica HEMA analyzers with integrated digital morphology, slide staining, and lab automation. | Supports standardized workflows, high accuracy, and seamless high-volume testing |
|
|
It offers hematology analyzers, digital morphology (MC-80), and automation lines (CAL 8000) with advanced fluorescence-based technologies. | Improves diagnostic accuracy, enables high-throughput testing, and reduces turnaround time through automation |
|
|
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The stakeholders in the market for hematology analyzers and reagents include companies manufacturing hematology analyzers, reagent suppliers, other consumables suppliers, distributors, final consumers such as hospitals and laboratories, and government regulatory bodies that control the market by ensuring quality standards. These manufacturing companies are engaged in the design and production of technologically advanced hematology analyzers capable of automating tasks, conducting multiparameter and morphometric analyses using computers, and interpreting results using artificial intelligence. Suppliers of reagents and other consumables provide the needed components, including diluents, lytic solutions, stains, and calibration fluids. The distributors and group purchasing organizations are engaged in distributing products to hospitals and laboratories and negotiating pricing terms. Government regulatory bodies, such as the FDA in the US and the EMA in Europe, ensure quality standards through market oversight, particularly by approving medical devices. Key companies operating in this ecosystem include Abbott Laboratories (US), Danaher Corporation (US), Siemens Healthineers (Germany), Sysmex Corporation (Japan), Bio-Rad Laboratories (US), Horiba (Japan), Nihon Kohden (Japan), and Boule Diagnostics AB (Sweden).
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Based on product & service, the hematology analyzers and reagents market is segmented into hematology, hemostasis, and immunohematology products & services. These segments are further categorized into reagents & consumables, instruments, and services. In 2025, the hematology products & services accounted for the largest share of 60.5% of the hematology analyzers and reagents market. The large share of this segment can be attributed to factors such as the increasing preference towards automation; the growing adoption of POC testing hematology analyzers in emerging economies; the launch of technologically advanced hematology products; the trend of the “reagent rental” business model; and the availability of a wide range of services from hematology analyzer providers.
Based on the price range, the hematology analyzers and reagents market is segmented into high-range, mid-range, and low-range analyzers. These instruments are categorized based on their throughput values, the number of tests performed per hour, and price variation. Low-range hematology analyzers accounted for the largest share of 51.5% of the hematology analyzers market in 2025. The large share of this segment can primarily be attributed to the low cost per test using these instruments, coupled with high adoption in end-user settings due to affordability.
The hematology analyzers and reagents market is segmented based on application into anemia, blood cancer, hemorrhagic conditions, infectious diseases, immune system disorders, and other applications. The infectious disease segment is expected to register the highest growth rate of 7.6% during the forecast period. The growth is attributed to the increasing dependence of healthcare professionals on hematological tests for detecting infectious diseases in early stages due to the inclusion of biomarkers (WBC differentials, NLR) in CBC tests.
Based on the usage type, the global hematology analyzers and reagents market is classified into standalone and point-of-care analyzers. The standalone analyzers segment accounted for the largest share of 59% of the hematology analyzers and reagents market in 2025. Among the two, the standalone analyzer segment has the leading market share of 59% in 2025, owing to the capability of handling large volumes of samples along with accuracy in analysis, integration with LIS, and having multiple parameters such as 5-part DIFF, reticulocytes, and abnormal flag cells.
By end user, the hematology analyzers and reagents market is segmented into commercial service providers, hospital laboratories, government reference laboratories, and research & academic institutes. Commercial service providers accounted for the largest share, at 46.1%, in 2025. The large share and high growth rate of this end-user segment can primarily be attributed to the growing outsourcing of R&D activities to commercial service providers, especially in emerging economies, and the competitive benefits offered by these providers as compared to hospitals (such as affordable service costs, efficient turnaround time, and efficient management for sample collection).
REGION
Asia Pacific to be the fastest-growing region in hematology analyzers & reagents market during the forecast period.
The market in Asia Pacific is expected to grow at the highest CAGR during the forecast period. This is because the region includes countries such as China, India, South Korea, Taiwan, and Singapore, where there has been an upsurge in both infections and chronic diseases amongst the people. This, in turn, has raised the demand for diagnostic tests. Also, factors responsible for growth include increased availability of healthcare facilities, more diagnostic centers, and the adoption of low-cost, effective analyzers. Growth is also due to increased awareness of early diagnosis. Additionally, innovative technologies, including POC (portable) analyzers, can contribute towards growth.
HEMATOLOGY ANALYZERS AND REAGENTS MARKET: COMPANY EVALUATION MATRIX
The hematology analyzers and reagents market has witnessed the presence of some dominant market players, including Abbott Laboratories, Danaher, Siemens Healthineers, Sysmex Corporation, Bio-Rad Laboratories, and Horiba, who are highly known for their dominance in the market, strong product portfolio, high levels of research and development activities, and well-established sales and distribution channels globally. In addition to the above-mentioned market players, some other emerging and niche market players, such as Drucker Diagnostics, ELITechGroup SAS, Accurex, and Analyticon Biotechnologies GmbH, are increasing their market share owing to their specialization and cost efficiency. Although these market players do not hold strong positions as compared to the leading market players, their offerings make them competitive in the market.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Sysmex Corporation (Japan)
- Danaher Corporation (US)
- Siemens Healthineers (Germany)
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China)
- Abbott Laboratories (US)
- Diatron (Hungary)
- Drew Scientific (US)
- Bio-Rad Laboratories, Inc. (US)
- Horiba, Ltd. (Japan)
- Nihon Kohden Corporation (Japan)
- EKF Diagnostics Holdings PLC (UK)
- Boule Diagnostics AB (Sweden)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Bio Systems (Spain)
- QuidelOrtho Corporation (US)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2026 (Value) | USD 7.57 Billion |
| Market Size in 2031 (Value) | USD 10.33 Billion |
| Growth Rate | CAGR of 6.4% from 2026 to 2031 |
| Years Considered | 2024–2031 |
| Base Year | 2025 |
| Forecast Period | 2026–2031 |
| Units Considered | Value (USD Million/Billion) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regions Covered | North America, Asia Pacific, Europe, Latin America, Middle East & Africa |
WHAT IS IN IT FOR YOU: HEMATOLOGY ANALYZERS AND REAGENTS MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Hematology Analyzers & Reagents Manufacturer |
|
|
| Healthcare Provider / Diagnostic Laboratory |
|
|
RECENT DEVELOPMENTS
- March 2025 : Sysmex America, Inc. announced the introduction of the Sysmex XQ-320, which is a new addition to the 3-part differential hematology analyzer family. The instrument is ideal for laboratories requiring efficient CBC testing at high throughput. It has a maximum throughput of 70 samples per hour, provides results within 60 seconds, and integrates BeyondCare Quality Monitor, providing greater efficiency and automation for North and South American users.
- December 2025 : Sysmex CN-700 (an automated hemostasis analyzer) was launched by Sysmex Corporation in Japan. This automated analyzer features a compact design with performance equivalent to other expensive models, a simpler workflow for easier handling, and quality control and traceability functions in accordance with ISO 15189 standards.
- January 2026 : The HORIBA Yumizen H500 CRP was certified under the CE IVDR category by the HORIBA Life Science Division. The benchtop analyzer combines a 5-part DIFF hematology test with rapid CRP test capabilities from a single blood sample. The integration of both tests helps in diagnosing infection and inflammation.
- March 2025 : The DxH 900 Hematology Analyzer from Beckman Coulter was launched in the Asia-Pacific region.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
4
MARKET OVERVIEW
43
4.2.1.1
RAPID INTEGRATION OF AI TO ENHANCE DIAGNOSTIC ACCURACY AND OPTIMIZE HEMATOLOGY WORKFLOWS
4.2.1.2
GROWING PREFERENCE FOR HIGH-PARAMETER AND MULTI-FUNCTIONAL TESTING
4.2.1.3
MOUNTING DEMAND FOR COST-EFFICIENT HEMATOLOGY ANALYZERS
4.2.2.1
HIGH COST OF ADVANCED HEMATOLOGY ANALYZERS
4.2.2.2
LIMITED ACCURACY OF DIGITAL MORPHOLOGY ANALYZERS IN DETECTING RARE AND COMPLEX CELL ABNORMALITIES
4.2.3.1
EXPANSION OF AI-ENABLED TELE-HEMATOLOGY AND REMOTE DIAGNOSTICS
4.2.3.2
ADOPTION OF PRECISION DIAGNOSTICS ENABLING ADVANCED CELL PROFILING, RARE CELL DETECTION, AND EARLY DISEASE IDENTIFICATION
4.2.4.1
COMPLEXITY IN MANAGING AND INTERPRETING DATA GENERATED BY NEXT-GENERATION HEMATOLOGY ANALYZERS
4.2.4.2
SHORTAGE OF LABORATORY WORKFORCE
4.4
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
52
5.1
PORTER’S FIVE FORCES ANALYSIS
5.1.1
INTENSITY OF COMPETITIVE RIVALRY
5.1.2
BARGAINING POWER OF BUYERS
5.1.3
BARGAINING POWER OF SUPPLIERS
5.1.4
THREAT OF NEW ENTRANTS
5.1.5
THREAT OF SUBSTITUTES
5.2
MACROECONOMIC OUTLOOK
5.2.2
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
5.2.3
MACROECONOMIC OUTLOOK FOR EUROPE
5.2.4
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
5.2.5
MACROECONOMIC OUTLOOK FOR LATIN AMERICA
5.2.6
MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
5.2.7
TRENDS IN GLOBAL IN-VITRO DIAGNOSTICS (IVD) INDUSTRY
5.2.8
TRENDS IN GLOBAL POINT-OF-CARE (POC) DIAGNOSTICS INDUSTRY
5.5.1
PRICING TREND OF HEMATOLOGY INSTRUMENTS, BY REGION, 2023–2025
5.5.2
AVERAGE SELLING PRICE OF HEMATOLOGY ANALYZERS AND REAGENTS, BY PRICE RANGE, 2025
5.6.1
IMPORT DATA (HS CODE 902780)
5.6.2
EXPORT DATA (HS CODE 902780)
5.7
KEY CONFERENCES AND EVENTS, 2026–2027
5.8
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.9
INVESTMENT AND FUNDING SCENARIO
5.10.1
DETECTION OF ABNORMAL WBC POPULATIONS IN HIGH WBC COUNT CASES USING XN-SERIES AUTOMATED HEMATOLOGY ANALYZER
5.10.2
MONITORING AND DETECTION OF ACUTE MYELOBLASTIC LEUKEMIA (AML-M1) USING ADVANCED HEMATOLOGY ANALYZERS
5.10.3
DETECTION OF MICROCYTIC ANEMIA WITH THROMBOCYTOSIS THROUGH ADVANCED SCATTERGRAM ANALYSIS
5.11
IMPACT OF US TARIFFS – HEMATOLOGY ANALYZERS AND REAGENTS MARKET
5.11.3
PRICE IMPACT ANALYSIS
5.11.4
IMPACT ON COUNTRIES/REGIONS
5.11.5
IMPACT ON END USERS
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACTS, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
73
6.1.2
DIGITAL MORPHOLOGY ANALYZERS
6.2
COMPLEMENTARY TECHNOLOGIES
6.2.1
LABORATORY INFORMATION SYSTEMS
6.2.2
CLOUD & REMOTE DIAGNOSTICS
6.5
IMPACT OF AI/GEN AI ON HEMATOLOGY ANALYZERS AND REAGENTS MARKET
6.5.1
TOP USE CASES AND MARKET POTENTIAL
6.5.2
BEST PRACTICES FOLLOWED BY COMPANIES IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET
6.5.3
CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET
6.5.4
INTERCONNECTED ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.5.5
CLIENTS' READINESS TO ADOPT AI/GEN AI-INTEGRATED HEMATOLOGY ANALYZERS AND REAGENTS
6.6
SUCCESS STORIES AND REAL-WORLD APPLICATIONS
7
REGULATORY LANDSCAPE
83
7.1
REGIONAL REGULATIONS AND COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
8
CUSTOMER LANDSCAPE AND BUYER BEHAVIOR
90
8.1
DECISION-MAKING PROCESS
8.2
KEY STAKEHOLDERS IN BUYING PROCESS AND EVALUATION CRITERIA
8.2.1
KEY STAKEHOLDERS IN BUYING PROCESS
8.3
ADOPTION BARRIERS AND INTERNAL CHALLENGES
8.4
UNMET NEEDS OF VARIOUS END USERS
9
HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRICE RANGE
97
9.2
LOW-RANGE HEMATOLOGY ANALYZERS
9.2.1
LOW OPERATING EXPENSES TO ACCELERATE SEGMENTAL GROWTH
9.3
HIGH-RANGE HEMATOLOGY ANALYZERS
9.3.1
HIGH ACCURACY AND MULTI-PARAMETER APPROACH TO FUEL SEGMENTAL GROWTH
9.4
MID-RANGE HEMATOLOGY ANALYZERS
9.4.1
INTEGRATION WITH QUALITY CONTROL SOFTWARE TO SUPPORT SEGMENTAL GROWTH
10
HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY USAGE TYPE
103
10.2
STANDALONE ANALYZERS
10.2.1
INCREASING DEMAND FOR HIGH-THROUGHPUT AND AUTOMATED LABORATORY WORKFLOWS TO FOSTER SEGMENTAL GROWTH
10.3
POINT-OF-CARE ANALYZERS
10.3.1
SHIFTING PREFERENCE TOWARD DECENTRALIZED AND RAPID DIAGNOSTICS TO EXPEDITE SEGMENTAL GROWTH
11
HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE
107
11.2
HEMATOLOGY PRODUCTS & SERVICES
11.2.1
REAGENTS & CONSUMABLES
11.2.1.1
HEMATOLOGY REAGENTS
11.2.1.1.1
GROWING PREFERENCE FOR RENTAL BUSINESS MODELS TO DRIVE MARKET
11.2.1.2
HEMATOLOGY CONSUMABLES
11.2.1.2.1
REQUIREMENT FOR ACCURATE AND EFFICIENT BLOOD ANALYSIS IN LABORATORY WORKFLOWS TO SPUR DEMAND
11.2.1.3
CONTROLS & CALIBRATORS
11.2.1.3.1
ABILITY TO MONITOR MULTIPLE PARAMETERS TO BOOST SEGMENTAL GROWTH
11.2.1.4
SLIDE STAINERS & MAKERS
11.2.1.4.1
DETAILED VISUALIZATION OF CELLULAR MORPHOLOGY TO AUGMENT SEGMENTAL GROWTH
11.2.2.1
5-PART & 6-PART FULLY AUTOMATED HEMATOLOGY ANALYZERS
11.2.2.1.1
IDENTIFICATION AND CLASSIFICATION OF WBCS TO DRIVE MARKET
11.2.2.2
3-PART FULLY AUTOMATED HEMATOLOGY ANALYZERS
11.2.2.2.1
LOW MAINTENANCE COSTS TO CONTRIBUTE TO SEGMENTAL GROWTH
11.2.2.3
POINT-OF-CARE & SEMI-AUTOMATED TESTING HEMATOLOGY ANALYZERS
11.2.2.3.1
SHIFT TOWARD DECENTRALIZED, RAPID, AND MULTI-PARAMETER HEMATOLOGY TESTING TO SPUR DEMAND
11.2.3.1
HIGH ADOPTION OF DIAGNOSTIC TECHNIQUES TO BOOST SEGMENTAL GROWTH
11.3
HEMOSTASIS PRODUCTS & SERVICES
11.3.1
HEMOSTASIS REAGENTS & CONSUMABLES
11.3.1.1
EXPANDING USE IN COMPREHENSIVE COAGULATION TESTING AND SPECIALIZED DIAGNOSTICS TO FUEL SEGMENTAL GROWTH
11.3.2
HEMOSTASIS INSTRUMENTS
11.3.2.1
HIGH PRODUCTIVITY WITH LOW COMPLEXITIES TO DRIVE MARKET
11.3.3
HEMOSTASIS SERVICES
11.3.3.1
ADVANCEMENTS IN HEMOSTASIS DIAGNOSTIC TECHNIQUES TO SUPPORT SEGMENTAL GROWTH
11.4
IMMUNOHEMATOLOGY PRODUCTS & SERVICES
11.4.1
IMMUNOHEMATOLOGY REAGENTS & CONSUMABLES
11.4.1.1
USE TO ENSURE ACCURATE TRANSFUSION TESTING AND ENHANCE BLOOD SAFETY TO BOLSTER SEGMENTAL GROWTH
11.4.2
IMMUNOHEMATOLOGY INSTRUMENTS
11.4.2.1
GROWING AUTOMATION IN IMMUNOHEMATOLOGY LABS TO FOSTER SEGMENTAL GROWTH
11.4.3.1
PROVISION OF CUSTOMER-FOCUSED CARE TO SUPPORT SEGMENTAL GROWTH
12
HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY APPLICATION
128
12.2
HEMORRHAGIC CONDITIONS
12.2.1
INCREASING DEMAND FOR DECENTRALIZED AND FREQUENT MONITORING TO EXPEDITE SEGMENTAL GROWTH
12.3.1
NEED FOR RAPID SCREENING TO ACCELERATE SEGMENTAL GROWTH
12.4
IMMUNE SYSTEM DISORDERS
12.4.1
FOCUS ON ADVANCED BLOOD PROFILING TO FACILITATE SEGMENTAL GROWTH
12.5.1
ABILITY TO IDENTIFY ABNORMAL BLOOD CELLS AND MORPHOLOGICAL ABNORMALITIES TO DRIVE MARKET
12.6.1
SHIFT TOWARD ADVANCED RBC PARAMETER ANALYSIS TO BOOST SEGMENTAL GROWTH
13
HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY END USER
136
13.2
COMMERCIAL SERVICE PROVIDERS
13.2.1
HIGH EMPHASIS ON HIGH-VOLUME ROUTINE TESTING, PREVENTIVE SCREENING, AND ADVANCED DIAGNOSTICS TO DRIVE MARKET
13.3
HOSPITAL LABORATORIES
13.3.1
RISING NEED FOR REAL-TIME PATIENT DIAGNOSIS AND EMERGENCY TESTING TO EXPEDITE SEGMENTAL GROWTH
13.4
GOVERNMENT REFERENCE LABORATORIES
13.4.1
INCREASING NEED FOR LARGE-SCALE DISEASE SURVEILLANCE, SCREENING, AND DIAGNOSTIC STANDARDIZATION TO SPUR DEMAND
13.5
RESEARCH & ACADEMIC INSTITUTES
13.5.1
GROWING FOCUS ON ADVANCED DISEASE PROFILING, BIOMARKER DISCOVERY, AND TRANSLATIONAL RESEARCH TO BOOST SEGMENTAL GROWTH
14
HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION
142
14.2.1.1
RISING INCIDENCE OF ANEMIA AND HEMOPHILIA TO DRIVE MARKET
14.2.2.1
MOUNTING DEMAND FOR ACCURATE BLOOD DIAGNOSTICS TO BOLSTER MARKET GROWTH
14.3.1.1
INCREASING PREVALENCE OF ANEMIA TO CONTRIBUTE TO MARKET GROWTH
14.3.2.1
RISING ADOPTION OF AUTOMATED AND HIGH-THROUGHPUT HEMATOLOGY ANALYZERS TO SUPPORT MARKET GROWTH
14.3.3.1
HIGH INCIDENCE OF BLOOD-RELATED DISORDERS TO EXPEDITE MARKET GROWTH
14.3.4.1
GROWING ACCEPTANCE OF HEMATOLOGY-BASED DIAGNOSTICS TO BOOST MARKET GROWTH
14.3.5.1
RISING PREFERENCE FOR AUTOMATED AND HIGH-THROUGHPUT HEMATOLOGY SYSTEMS TO AUGMENT MARKET GROWTH
14.4.1.1
LARGE TARGET PATIENT POPULATION TO EXPEDITE MARKET GROWTH
14.4.2.1
RISING CASES OF INFLUENZA TO SUPPORT MARKET GROWTH
14.4.3.1
GOVERNMENT-LED PROCUREMENT INITIATIVES AND EXPANDING DIAGNOSTIC INFRASTRUCTURE TO FUEL MARKET GROWTH
14.4.4.1
INCREASING PREVALENCE OF CELIAC DISEASE TO DRIVE MARKET
14.4.5.1
STRONG FOCUS ON ADVANCED DIAGNOSTICS AND AUTOMATION TO CONTRIBUTE TO MARKET GROWTH
14.4.6
REST OF ASIA PACIFIC
14.5.1.1
INCREASING BURDEN OF ANEMIA AND INFECTIOUS DISEASES TO EXPEDITE MARKET GROWTH
14.5.2.1
MOUNTING DEMAND FOR DIAGNOSTIC TESTING TO ACCELERATE MARKET GROWTH
14.5.3
REST OF LATIN AMERICA
14.6
MIDDLE EAST & AFRICA
14.6.1
HIGH DISEASE AWARENESS, IMPROVING HEALTHCARE INFRASTRUCTURE, AND ADVANCED TREATMENT OPTIONS TO DRIVE MARKET
14.6.3
REST OF MIDDLE EAST & AFRICA
15
COMPETITIVE LANDSCAPE
186
15.2
KEY PLAYERS COMPETITIVE STRATEGIES/RIGHT TO WIN, 2022–2026
15.3
REVENUE ANALYSIS, 2021–2025
15.4
MARKET SHARE ANALYSIS, 2025
15.5
MARKET RANKING, 2025
15.6
COMPANY VALUATION AND FINANCIAL METRICS
15.8
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
15.8.5
COMPETITIVE FOOTPRINT: KEY PLAYERS, 2025
15.8.5.1
COMPANY FOOTPRINT
15.8.5.2
REGION FOOTPRINT
15.8.5.3
PRODUCT & SERVICE FOOTPRINT
15.8.5.4
APPLICATION FOOTPRINT
15.8.5.5
END USER FOOTPRINT
15.9
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
15.9.1
PROGRESSIVE COMPANIES
15.9.2
RESPONSIVE COMPANIES
15.9.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
15.9.5.1
DETAILED LIST OF KEY STARTUPS/SMES
15.9.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
15.10
COMPETITIVE SCENARIO
15.10.1
PRODUCT LAUNCHES AND APPROVALS
16
COMPANY PROFILES
208
16.1.1
SYSMEX CORPORATION
16.1.1.1
BUSINESS OVERVIEW
16.1.1.2
PRODUCTS OFFERED
16.1.1.3
RECENT DEVELOPMENTS
16.1.1.4.2
STRATEGIC CHOICES
16.1.1.4.3
WEAKNESSES AND COMPETITIVE THREATS
16.1.3
DANAHER CORPORATION
16.1.4
SIEMENS HEALTHINEERS AG
16.1.5
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
16.1.8
BIO-RAD LABORATORIES, INC.
16.1.10
NIHON KOHDEN CORPORATION
16.1.11
EKF DIAGNOSTICS HOLDINGS PLC
16.1.13
F. HOFFMANN-LA ROCHE LTD
16.1.14
BIOSYSTEMS DIAGNOSTICS
16.2.1
DRUCKER DIAGNOSTICS
16.2.7
SHENZHEN DYMIND BIOTECHNOLOGY CO., LTD.
16.2.10
RAYTO LIFE AND ANALYTICAL SCIENCES CO.,LTD.
16.2.11
ANALYTICON BIOTECHNOLOGIES GMBH
17
RESEARCH METHODOLOGY
265
17.2.1.1
LIST OF KEY SECONDARY SOURCES
17.2.1.2
KEY DATA FROM SECONDARY SOURCES
17.2.2.1
KEY DATA FROM PRIMARY SOURCES
17.2.2.2
PRIMARY RESEARCH OBJECTIVES
17.2.2.3
KEY INDUSTRY INSIGHTS
17.2.2.4
BREAKDOWN OF PRIMARIES
17.2.2.5
LIST OF PRIMARY INTERVIEW PARTICIPANTS
17.3
MARKET SIZE ESTIMATION
17.3.1
BOTTOM-UP APPROACH
17.6
MARKET SHARE ASSESSMENT
17.7
RESEARCH ASSUMPTIONS
17.8
RESEARCH LIMITATIONS
18.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
18.3
CUSTOMIZATION OPTIONS
TABLE 1
HEMATOLOGY ANALYZERS AND REAGENTS MARKET: INCLUSIONS AND EXCLUSIONS
TABLE 2
IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 3
POTENTIAL BIOMARKERS DETECTABLE BY NEXT-GENERATION HEMATOLOGY ANALYZERS
TABLE 4
HEMATOLOGY ANALYZERS AND REAGENTS MARKET: UNMET NEEDS
TABLE 5
STRATEGIC FOCUS OF TIER-1/2/3 PLAYERS
TABLE 6
IMPACT OF PORTER’S FIVE FORCES ANALYSIS
TABLE 7
NORTH AMERICA: MACROECONOMIC OUTLOOK
TABLE 8
EUROPE: MACROECONOMIC OUTLOOK
TABLE 9
ASIA PACIFIC: MACROECONOMIC OUTLOOK
TABLE 10
LATIN AMERICA: MACROECONOMIC OUTLOOK
TABLE 11
MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
TABLE 12
ROLE OF COMPANIES IN HEMATOLOGY ANALYZERS AND REAGENTS ECOSYSTEM
TABLE 13
PRICING TREND OF HEMATOLOGY INSTRUMENTS, BY REGION, 2023–2025 (USD THOUSAND)
TABLE 14
AVERAGE SELLING PRICE OF HEMATOLOGY ANALYZERS AND REAGENTS, BY PRICE RANGE, 2025 (USD THOUSAND)
TABLE 15
AVERAGE SELLING PRICE OF HEMATOLOGY REAGENTS & CONSUMABLES, BY KEY PLAYER, 2025 (USD THOUSAND)
TABLE 16
IMPORT DATA FOR HS CODE 902780-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 17
EXPORT DATA FOR HS CODE 902780-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 18
LIST OF KEY CONFERENCES AND EVENTS, 2026–2027
TABLE 19
US-ADJUSTED RECIPROCAL TARIFF RATES IN MEDTECH INDUSTRY
TABLE 20
TARIFF-INDUCED PRICE INCREASES FOR HEALTHCARE PRODUCTS
TABLE 21
INNOVATIONS AND PATENT REGISTRATIONS, 2020–2024
TABLE 22
KEY COMPANIES IMPLEMENTING AI/GEN AI IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET
TABLE 23
KEY APPLICATIONS AND CLINICAL OUTCOMES ENABLED BY HEMATOLOGY ANALYZERS
TABLE 24
NORTH AMERICA: LIST OF REGULATORY AUTHORITIES IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET
TABLE 25
EUROPE: LIST OF REGULATORY AUTHORITIES IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET
TABLE 26
ASIA PACIFIC: LIST OF REGULATORY AUTHORITIES IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET
TABLE 27
LATIN AMERICA: LIST OF REGULATORY AUTHORITIES IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET
TABLE 28
MIDDLE EAST & AFRICA: LIST OF REGULATORY AUTHORITIES IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET
TABLE 29
IMPACT OF CLIA 2024 ON HEMATOLOGY ANALYZERS AND REAGENTS MARKET
TABLE 30
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE (%)
TABLE 31
BUYING CRITERIA, BY PRODUCT & SERVICE
TABLE 32
HEMATOLOGY ANALYZERS AND REAGENTS MARKET: UNMET NEED ANALYSIS, BY END USER
TABLE 33
HEMATOLOGY ANALYZER SEGMENTATION, BY SYSTEM TYPE, PERFORMANCE, AND PRICING
TABLE 34
HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRICE RANGE, 2024–2031 (USD MILLION)
TABLE 35
LOW-RANGE HEMATOLOGY ANALYZERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 36
HIGH-RANGE HEMATOLOGY ANALYZERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 37
MID-RANGE HEMATOLOGY ANALYZERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 38
HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY USAGE TYPE, 2024–2031 (USD MILLION)
TABLE 39
STANDALONE ANALYZERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 40
POINT-OF-CARE ANALYZERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 41
HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 42
HEMATOLOGY PRODUCTS & SERVICES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 43
HEMATOLOGY PRODUCTS & SERVICES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 44
HEMATOLOGY REAGENTS & CONSUMABLES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 45
HEMATOLOGY REAGENTS & CONSUMABLES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 46
HEMATOLOGY REAGENTS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 47
HEMATOLOGY CONSUMABLES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 48
HEMATOLOGY CONTROLS & CALIBRATORS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 49
HEMATOLOGY SLIDE STAINERS & MAKERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 50
HEMATOLOGY INSTRUMENTS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 51
HEMATOLOGY INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 52
5-PART VS. 6-PART FULLY AUTOMATED HEMATOLOGY ANALYZERS
TABLE 53
5-PART & 6-PART FULLY AUTOMATED HEMATOLOGY ANALYZERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 54
3-PART FULLY AUTOMATED HEMATOLOGY ANALYZERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 55
POINT-OF-CARE & SEMI-AUTOMATED TESTING HEMATOLOGY ANALYZERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 56
HEMATOLOGY SERVICES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 57
HEMOSTASIS PRODUCTS & SERVICES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 58
HEMOSTASIS PRODUCTS & SERVICES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 59
HEMOSTASIS REAGENTS & CONSUMABLES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 60
HEMOSTASIS INSTRUMENTS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 61
HEMOSTASIS SERVICES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 62
IMMUNOHEMATOLOGY PRODUCTS & SERVICES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 63
IMMUNOHEMATOLOGY PRODUCTS & SERVICES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 64
IMMUNOHEMATOLOGY REAGENTS & CONSUMABLES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 65
IMMUNOHEMATOLOGY INSTRUMENTS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 66
IMMUNOHEMATOLOGY SERVICES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 67
HAEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 68
HEMORRHAGIC CONDITIONS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 69
INFECTIOUS DISEASES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 70
IMMUNE SYSTEM DISORDERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 71
BLOOD CANCER: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 72
ANEMIA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 73
OTHER APPLICATIONS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 74
HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 75
COMMERCIAL SERVICE PROVIDERS: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 76
HOSPITAL LABORATORIES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 77
GOVERNMENT REFERENCE LABORATORIES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 78
RESEARCH & ACADEMIC INSTITUTES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 79
HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 80
NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 81
NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 82
NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 83
NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 84
NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMOSTASIS PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 85
NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR IMMUNOHEMATOLOGY PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 86
NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRICE RANGE, 2024–2031 (USD MILLION)
TABLE 87
NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 88
NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY USAGE TYPE, 2024–2031 (USD MILLION)
TABLE 89
NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 90
US: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 91
CANADA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 92
EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 93
EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 94
EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 95
EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 96
EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMOSTASIS PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 97
EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR IMMUNOHEMATOLOGY PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 98
EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRICE RANGE, 2024–2031 (USD MILLION)
TABLE 99
EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 100
EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY USAGE TYPE, 2024–2031 (USD MILLION)
TABLE 101
EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 102
GERMANY: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 103
FRANCE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 104
UK: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 105
ITALY: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 106
SPAIN: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 107
REST OF EUROPE: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 108
ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 109
ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 110
ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 111
ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 112
ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMOSTASIS PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 113
ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR IMMUNOHEMATOLOGY PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 114
ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRICE RANGE, 2024–2031 (USD MILLION)
TABLE 115
ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 116
ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY USAGE TYPE, 2024–2031 (USD MILLION)
TABLE 117
ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 118
CHINA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 119
JAPAN: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 120
INDIA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 121
AUSTRALIA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 122
SOUTH KOREA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 123
REST OF ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 124
LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 125
LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 126
LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 127
LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 128
LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMOSTASIS PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 129
LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR IMMUNOHEMATOLOGY PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 130
LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY ANALYZERS AND REAGENTS, BY PRICE RANGE, 2024–2031 (USD MILLION)
TABLE 131
LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY ANALYZERS AND REAGENTS, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 132
LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY ANALYZERS AND REAGENTS, BY USAGE TYPE, 2024–2031 (USD MILLION)
TABLE 133
LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY ANALYZERS AND REAGENTS, BY END USER, 2024–2031 (USD MILLION)
TABLE 134
BRAZIL: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 135
MEXICO: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 136
REST OF LATIN AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 137
MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 138
MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 139
MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 140
MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMATOLOGY INSTRUMENTS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 141
MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR HEMOSTASIS PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 142
MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET FOR IMMUNOHEMATOLOGY PRODUCTS & SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 143
MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRICE RANGE, 2024–2031 (USD MILLION)
TABLE 144
MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 145
MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY USAGE TYPE, 2024–2031 (USD MILLION)
TABLE 146
MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 147
GCC COUNTRIES: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 148
REST OF MIDDLE EAST & AFRICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION)
TABLE 149
HEMATOLOGY ANALYZERS AND REAGENTS MARKET: OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS, JANUARY 2022–MARCH 2026
TABLE 150
HEMATOLOGY ANALYZERS AND REAGENTS MARKET: DEGREE OF COMPETITION, 2025
TABLE 151
HEMATOLOGY ANALYZERS AND REAGENTS MARKET: REGION FOOTPRINT
TABLE 152
HEMATOLOGY ANALYZERS AND REAGENTS MARKET: PRODUCT & SERVICE FOOTPRINT
TABLE 153
HEMATOLOGY ANALYZERS AND REAGENTS MARKET: APPLICATION FOOTPRINT
TABLE 154
HEMATOLOGY ANALYZERS AND REAGENTS MARKET: END USER FOOTPRINT
TABLE 155
HEMATOLOGY ANALYZERS AND REAGENTS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 156
HEMATOLOGY ANALYZERS AND REAGENTS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
TABLE 157
HEMATOLOGY ANALYZERS AND REAGENTS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2026
TABLE 158
HEMATOLOGY ANALYZERS AND REAGENTS MARKET: DEALS, JANUARY 2022–MARCH 2026
TABLE 159
HEMATOLOGY ANALYZERS AND REAGENTS MARKET: EXPANSIONS, JANUARY 2022–MARCH 2026
TABLE 160
SYSMEX CORPORATION: COMPANY OVERVIEW
TABLE 161
SYSMEX CORPORATION: PRODUCTS OFFERED
TABLE 162
SYSMEX CORPORATION: DEALS, JANUARY 2022–MARCH 2026
TABLE 163
SYSMEX CORPORATION: EXPANSIONS, JANUARY 2022–MARCH 2026
TABLE 164
ABBOTT: COMPANY OVERVIEW
TABLE 165
ABBOTT: PRODUCTS OFFERED
TABLE 166
ABBOTT: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2026
TABLE 167
DANAHER CORPORATION: COMPANY OVERVIEW
TABLE 168
DANAHER CORPORATION: PRODUCTS OFFERED
TABLE 169
DANAHER CORPORATION: DEALS, JANUARY 2022–NOVEMBER 2025
TABLE 170
SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
TABLE 171
SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED
TABLE 172
SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022– MARCH 2026
TABLE 173
SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2022– MARCH 2026
TABLE 174
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW
TABLE 175
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: PRODUCTS OFFERED
TABLE 176
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–AUGUST 2025
TABLE 177
DIATRON: COMPANY OVERVIEW
TABLE 178
DIATRON: PRODUCTS OFFERED
TABLE 179
DIATRON: EXPANSIONS, JANUARY 2022–MARCH 2026
TABLE 180
DREW SCIENTIFIC: COMPANY OVERVIEW
TABLE 181
DREW SCIENTIFIC: PRODUCTS OFFERED
TABLE 182
BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
TABLE 183
BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED
TABLE 184
BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2026
TABLE 185
HORIBA: COMPANY OVERVIEW
TABLE 186
HORIBA: PRODUCTS OFFERED
TABLE 187
HORIBA: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2026
TABLE 188
NIHON KOHDEN CORPORATION: COMPANY OVERVIEW
TABLE 189
NIHON KOHDEN CORPORATION: PRODUCTS OFFERED
TABLE 190
NIHON KOHDEN CORPORATION: DEALS, JANUARY 2022–MARCH 2026
TABLE 191
EKF DIAGNOSTICS HOLDINGS PLC: COMPANY OVERVIEW
TABLE 192
EKF DIAGNOSTICS HOLDINGS PLC: PRODUCTS OFFERED
TABLE 193
EKF DIAGNOSTICS HOLDINGS PLC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2026
TABLE 194
BOULE: COMPANY OVERVIEW
TABLE 195
BOULE: PRODUCTS OFFERED
TABLE 196
BOULE: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2026
TABLE 197
BOULE: DEALS, JANUARY 2022–MARCH 2026
TABLE 198
F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW
TABLE 199
F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED
TABLE 200
F. HOFFMANN-LA ROCHE LTD: DEALS, JANUARY 2022–MARCH 2025
TABLE 201
BIOSYSTEMS DIAGNOSTICS: COMPANY OVERVIEW
TABLE 202
BIOSYSTEMS DIAGNOSTICS: PRODUCTS OFFERED
TABLE 203
DRUCKER DIAGNOSTICS: COMPANY OVERVIEW
TABLE 204
ACCUREX: COMPANY OVERVIEW
TABLE 205
STRECK: COMPANY OVERVIEW
TABLE 206
NEOMEDICA: COMPANY OVERVIEW
TABLE 207
EVERLIFE CPC: COMPANY OVERVIEW
TABLE 208
MERIL: COMPANY OVERVIEW
TABLE 209
SHENZHEN DYMIND BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW
TABLE 210
PZ CORMAY S.A.: COMPANY OVERVIEW
TABLE 211
PIXCELL MEDICAL: COMPANY OVERVIEW
TABLE 212
RAYTO LIFE AND ANALYTICAL SCIENCES CO.,LTD.: COMPANY OVERVIEW
TABLE 213
ANALYTICON BIOTECHNOLOGIES GMBH: COMPANY OVERVIEW
TABLE 214
HEMATOLOGY ANALYZERS AND REAGENTS MARKET: RESEARCH ASSUMPTIONS
TABLE 215
HEMATOLOGY ANALYZERS AND REAGENTS MARKET: RISK ANALYSIS
FIGURE 1
HEMATOLOGY ANALYZERS AND REAGENTS MARKET SEGMENTATION AND REGIONAL SCOPE
FIGURE 2
HEMATOLOGY ANALYZERS AND REAGENTS MARKET: DURATION CONSIDERED
FIGURE 3
HEMATOLOGY ANALYZERS AND REAGENTS MARKET SCENARIO
FIGURE 4
GLOBAL HEMATOLOGY ANALYZERS AND REAGENTS MARKET SIZE, 2024–2031
FIGURE 5
MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET, 2022–2026
FIGURE 6
DISRUPTIONS INFLUENCING GROWTH OF HEMATOLOGY ANALYZERS AND REAGENTS MARKET
FIGURE 7
HIGH-GROWTH SEGMENTS IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET, 2026–2031
FIGURE 8
ASIA PACIFIC TO REGISTER HIGHEST CAGR IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET DURING FORECAST PERIOD
FIGURE 9
INCREASING HEALTHCARE INVESTMENTS AND AWARENESS ABOUT EARLY DISEASE DIAGNOSIS TO DRIVE HEMATOLOGY ANALYZERS AND REAGENTS MARKET
FIGURE 10
NORTH AMERICA TO COMMAND LARGEST MARKET SHARE DURING STUDY PERIOD
FIGURE 11
COMMERCIAL SERVICE PROVIDERS AND CHINA ACCOUNTED FOR LARGEST MARKET SHARE IN ASIA PACIFIC IN 2025
FIGURE 12
CHINA TO REGISTER HIGHEST GROWTH RATE FROM 2026 TO 2031
FIGURE 13
DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 14
PORTER’S FIVE FORCES ANALYSIS
FIGURE 15
HEMATOLOGY ANALYZERS AND REAGENTS VALUE CHAIN ANALYSIS
FIGURE 16
HEMATOLOGY ANALYZERS AND REAGENTS ECOSYSTEM ANALYSIS
FIGURE 17
PRICING TREND OF HEMATOLOGY INSTRUMENTS, BY REGION, 2023–2025
FIGURE 18
AVERAGE SELLING PRICE OF HEMATOLOGY ANALYZERS AND REAGENTS, BY PRICE RANGE, 2025
FIGURE 19
IMPORT DATA FOR HS CODE 902780-COMPLIANT PRODUCTS FOR TOP FIVE COUNTRIES, 2021–2025
FIGURE 20
EXPORT DATA FOR HS CODE 902780-COMPLIANT PRODUCTS FOR TOP FIVE COUNTRIES, 2021–2025
FIGURE 21
TRENDS/DISRUPTIONS INFLUENCING CUSTOMER BUSINESS
FIGURE 22
INVESTMENT AND FUNDING SCENARIO, 2019–2023
FIGURE 23
NUMBER OF DEALS, BY KEY PLAYER, 2019–2023
FIGURE 24
DEAL VALUES, BY KEY PLAYER, 2019–2023
FIGURE 25
PATENTS APPLIED AND GRANTED, 2016–2025
FIGURE 26
KEY AI/GEN AI USE CASES IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET
FIGURE 27
HEMATOLOGY ANALYZER AND REAGENTS MARKET: DECISION-MAKING FACTORS
FIGURE 28
INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE
FIGURE 29
KEY BUYING CRITERIA, BY PRODUCT & SERVICE
FIGURE 30
HEMATOLOGY ANALYZERS AND REAGENTS MARKET: UNMET NEED ANALYSIS
FIGURE 31
NORTH AMERICA: HEMATOLOGY ANALYZERS AND REAGENTS MARKET SNAPSHOT
FIGURE 32
ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET SNAPSHOT
FIGURE 33
HEMATOLOGY ANALYZERS AND REAGENTS MARKET: REVENUE ANALYSIS OF TOP FOUR PLAYERS, 2021−2025
FIGURE 34
MARKET SHARE ANALYSIS OF COMPANIES OFFERING HEMATOLOGY ANALYZERS AND REAGENTS, 2025
FIGURE 35
HEMATOLOGY ANALYZERS AND REAGENTS MARKET: RANKING OF KEY PLAYERS, 2025
FIGURE 36
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 37
FINANCIAL METRICS (EV/EBITDA)
FIGURE 38
PRODUCT COMPARATIVE ANALYSIS
FIGURE 39
HEMATOLOGY ANALYZERS AND REAGENTS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 40
HEMATOLOGY ANALYZERS AND REAGENTS MARKET: COMPANY FOOTPRINT
FIGURE 41
HEMATOLOGY ANALYZERS AND REAGENTS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 42
SYSMEX CORPORATION: COMPANY SNAPSHOT (2024)
FIGURE 43
ABBOTT: COMPANY SNAPSHOT (2025)
FIGURE 44
DANAHER CORPORATION: COMPANY SNAPSHOT (2024)
FIGURE 45
SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024)
FIGURE 46
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY SNAPSHOT (2025)
FIGURE 47
BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 48
HORIBA: COMPANY SNAPSHOT (2025)
FIGURE 49
NIHON KOHDEN CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 50
EKF DIAGNOSTICS HOLDINGS PLC: COMPANY SNAPSHOT (2024)
FIGURE 51
BOULE: COMPANY SNAPSHOT (2024)
FIGURE 52
F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2025)
FIGURE 53
HEMATOLOGY ANALYZERS AND REAGENTS MARKET: RESEARCH DATA
FIGURE 54
HEMATOLOGY ANALYZERS AND REAGENTS MARKET: RESEARCH DESIGN
FIGURE 55
DATA CAPTURED FROM SECONDARY SOURCES
FIGURE 56
PRIMARY SOURCES
FIGURE 57
CORE FINDINGS FROM INDUSTRY EXPERTS
FIGURE 58
BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 59
BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 60
RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
FIGURE 61
HEMATOLOGY ANALYZERS AND REAGENTS MARKET: BOTTOM-UP APPROACH
FIGURE 62
HEMATOLOGY ANALYZERS AND REAGENTS MARKET SIZE ESTIMATION (APPROACH 1)
FIGURE 63
HEMATOLOGY ANALYZERS AND REAGENTS MARKET: TOP-DOWN APPROACH
FIGURE 64
HEMATOLOGY ANALYZERS AND REAGENTS MARKET: MARKET SIZE ESTIMATION
FIGURE 65
HEMATOLOGY ANALYZERS AND REAGENTS MARKET: DATA TRIANGULATION
Methodology
This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.
Secondary Research
The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the hematology analyzers and reagents market. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends, to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the hematology analyzers and reagents market. The primary sources from the demand side include OEMs, private and contract testing organizations, and service providers, among others. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends & key market dynamics.
*Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
Note: Companies are classified into tiers based on their total revenue. As of 2022, Tier 1 = >USD 2 billion, Tier 2 = USD 50 million to USD 2 billion, and Tier 3 = <USD 50 million.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
In this report, the market size of hematology analyzers & reagents was determined using the revenue share analysis of leading players. For this purpose, key market players were identified, and their market revenues were determined using insights gathered during the primary and secondary research phases. Secondary research included analyzing the annual and financial reports of the top market players. In contrast, primary research included extensive interviews with key opinion leaders, including CEOs, directors, and senior marketing executives.
Segmental revenues were calculated based on the revenue mapping of major solution/service providers to calculate the global market value. This process involved the following steps:
- Generating a list of major global players operating in the hematology analyzers & reagents market
- Mapping annual revenues generated by major global players from the product & services segment (or nearest reported business unit/product category)
- Revenue mapping of major players to cover a major share of the global market, as of 2025
- Extrapolating the global value of the hematology analyzers & reagents market industry.
Data Triangulation
After arriving at the overall market size from the market size estimation process explained above, the global hematology analyzers and reagents market was split into segments and subsegments. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides. Additionally, the hematology analyzers and reagents market was validated using both top-down and bottom-up approaches.
Market Definition
The hematology analyzers and reagents market can be defined as the global industry involved in the design, development, and sale of instruments and consumables used for blood analysis. It involves the use of various types of hematology analyzers, including manual, semiautomatic, and automatic ones – 3-part differential analyzers, 5-part/6-part full-automatic analyzers, as well as POCT hematology testing systems. Tests performed with them include CBC, WBC differentials, hemoglobin analysis, and platelet counts. They are widely used in the diagnosis of anemia, infectious diseases, hematologic malignancies, and other blood disorders.
Reagents for hematology include diluents, lysing reagents, stains, controls/calibrators, and other consumables required in the course of testing to achieve accurate, reliable results. In addition to the hematology segment, the market includes hemostasis and immunohematology segments. Thus, it offers a wider range of products/services.
The market is expected to grow significantly due to rising demand for blood analysis across hospitals, labs, research institutes, and POCT sites. It is due to advancements in technology and automation in the industry.
Key Stakeholders
- Manufacturers of hematology analyzers and reagents
- Suppliers, distributors, and channel partners of hematology analyzers and reagents
- Clinical research organizations
- Research laboratories and academic institutes
- Hospitals and clinics
- Research laboratories and CROs
- Research and academic institutes
- Government and private laboratories
- Market research and consulting firms
Report Objectives
- To define, describe, and forecast the hematology analyzers and reagents market on the basis of product and services, price range, application, usage type, end user, and region
- To provide detailed information regarding the major factors influencing the growth potential of the global hematology analyzers and reagents market (drivers, restraints, opportunities, challenges, and trends)
- To analyze the micro markets with respect to individual growth trends, future prospects, and contributions to the global hematology analyzers and reagents market
- To analyze key growth opportunities in the global hematology analyzers and reagents market for key stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of market segments and/or subsegments with respect to five major regions, namely, North America (the US and Canada), Europe (Germany, the UK, France, Italy, Spain, and Rest of Europe), Asia Pacific (Japan, China, India, Australia, South Korea, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and the Middle East and Africa (GCC Countries and Rest of MEA)
- To profile the key players in the global hematology analyzers and reagents market and comprehensively analyze their market shares and core competencies
- To track and analyze the competitive developments undertaken in the global hematology analyzers and reagents market, such as agreements, expansions, and product launches
Available customizations:
Based on the provided market data, MarketsandMarkets offers customizations to meet the company’s specific needs. The following customization options are available for the present global hematology analyzers and reagents market report:
Product Analysis
- Product matrix, which gives a detailed comparison of the product portfolios of the top fifteen companies
Company Information
- Detailed analysis and profiling of additional market players (up to 13)
Geographic Analysis
- Further breakdown of the Rest of Europe's hematology analyzers and reagents market into Russia, Belgium, the Netherlands, Switzerland, Austria, Finland, Sweden, Poland, and Portugal, among other countries
- Further breakdown of the Rest of Asia Pacific hematology analyzers and reagents market into Singapore, Taiwan, New Zealand, the Philippines, Malaysia, and other Asia Pacific countries
- Further breakdown of the Rest of the Latin America hematology analyzers and reagents market into Argentina, Chile, Peru, and Colombia, among other countries.
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Hematology Analyzers and Reagents Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
JAYANT RAJPUROHIT
Director of Market Insights, Data and Analytics
SFI Health,
Leading Pharmaceutical Company
We at SFI Health approached MarketsandMarkets for an Opportunity Assessment on "Incidence and Prevalence of Focus Indications" as we wanted to know the most attractive HCPs like Physician, Functional MD, Naturopath and Pharmacist. The project was critical for us to ensure our focus on the right target which would enable sustainable growth and profitability for SFI Health. The business insights provided exceeded our expectations and we were extremely impressed. The team at MarketsandMarkets is highly professional and detail oriented and very well understood our business needs. MarketsandMarkets offers a unique combination of expertise and dedicated engagement model. We identified 2 new products to be launched in coming months, based on the research findings provided by MarketsandMarkets. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
BEATRIZ DE LA CALLE
Head of Commercial Analytics
Qualicaps,
Leading Pharmaceutical Company
We partnered with MarketsandMarkets for an assessment study on hard empty capsules. The team was extremely professional in understanding our business requirements and we received timely responses to all our queries. The market intelligence and the recommendations has met our business requirements. We were extremely impressed to see the final study results; it really exceeded our expectations. The market intelligence offered by MarketsandMarkets, and clarity on next steps will help us achieve our business objective for the Year 2021. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
Bob Williams,
Senior Director Business Development & Innovation
Bracco Diagnostics Inc.,
Italian Multinational in life sciences sector and a World Leader in imaging diagnostics
We were pleased with targeted insights that MarketsandMarkets identified from a custom study on the 'Radiation Dose Management Solutions Market'. Your team identified and characterized the market participants as well as underlying trends accurately. This study was useful to Bracco in formulating business strategies for our dose monitoring product lines and we thank MarketsandMarkets for the job well done.
Cody Coonradt,
Market Development and Strategy Manager
3M Health Information Systems,
Leader in Health care Coding, Payment & Analytics Solutions.
The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarketsandMarkets, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer.
Their customer first approach and high value engagement model, have given us great analysis and excellent value for money
Previous Next
